These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 2469721)

  • 21. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations.
    Ahlers JD; Pendleton CD; Dunlop N; Minassian A; Nara PL; Berzofsky JA
    J Immunol; 1993 Jun; 150(12):5647-65. PubMed ID: 8515081
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunizations of monkeys with synthetic peptides disclose conserved areas on gp120 of human immunodeficiency virus type 1 associated with cross-neutralizing antibodies and T-cell recognition.
    Vahlne A; Horal P; Eriksson K; Jeansson S; Rymo L; Hedström KG; Czerkinsky C; Holmgren J; Svennerholm B
    Proc Natl Acad Sci U S A; 1991 Dec; 88(23):10744-8. PubMed ID: 1961741
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunodominant B-cell clones responsive to an HIV-1 neutralization and cell fusion inhibition epitope in chimpanzee-to-chimpanzee passages of HTLV-IIIB and LAV-1.
    Goudsmit J; Bakker M; Smit L
    Res Virol; 1989; 140(5):405-18. PubMed ID: 2479965
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Variant-specific monoclonal and group-specific polyclonal human immunodeficiency virus type 1 neutralizing antibodies raised with synthetic peptides from the gp120 third variable domain.
    Laman JD; Schellekens MM; Abacioglu YH; Lewis GK; Tersmette M; Fouchier RA; Langedijk JP; Claassen E; Boersma WJ
    J Virol; 1992 Mar; 66(3):1823-31. PubMed ID: 1637373
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antisera raised against the second variable region of the external envelope glycoprotein of human immunodeficiency virus type 1 cross-neutralize and show an increased neutralization index when they act together with antisera to the V3 neutralization epitope.
    Davis D; Stephens DM; Carne CA; Lachmann PJ
    J Gen Virol; 1993 Dec; 74 ( Pt 12)():2609-17. PubMed ID: 7506300
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Generation and characterization of monoclonal antibodies to the putative CD4-binding domain of human immunodeficiency virus type 1 gp120.
    Sun NC; Ho DD; Sun CR; Liou RS; Gordon W; Fung MS; Li XL; Ting RC; Lee TH; Chang NT
    J Virol; 1989 Sep; 63(9):3579-85. PubMed ID: 2474670
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A chemically defined synthetic vaccine model for HIV-1.
    Nardelli B; Lu YA; Shiu DR; Delpierre-Defoort C; Profy AT; Tam JP
    J Immunol; 1992 Feb; 148(3):914-20. PubMed ID: 1370524
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human immunodeficiency virus type 1 challenge of chimpanzees immunized with recombinant envelope glycoprotein gp120.
    Berman PW; Groopman JE; Gregory T; Clapham PR; Weiss RA; Ferriani R; Riddle L; Shimasaki C; Lucas C; Lasky LA
    Proc Natl Acad Sci U S A; 1988 Jul; 85(14):5200-4. PubMed ID: 2455898
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein.
    Matthews TJ; Langlois AJ; Robey WG; Chang NT; Gallo RC; Fischinger PJ; Bolognesi DP
    Proc Natl Acad Sci U S A; 1986 Dec; 83(24):9709-13. PubMed ID: 2432599
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brucella abortus conjugated with a peptide derived from the V3 loop of human immunodeficiency virus (HIV) type 1 induces HIV-specific cytotoxic T-cell responses in normal and in CD4+ cell-depleted BALB/c mice.
    Lapham C; Golding B; Inman J; Blackburn R; Manischewitz J; Highet P; Golding H
    J Virol; 1996 May; 70(5):3084-92. PubMed ID: 8627787
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Brucella abortus conjugated with a gp120 or V3 loop peptide derived from human immunodeficiency virus (HIV) type 1 induces neutralizing anti-HIV antibodies, and the V3-B. abortus conjugate is effective even after CD4+ T-cell depletion.
    Golding B; Inman J; Highet P; Blackburn R; Manischewitz J; Blyveis N; Angus RD; Golding H
    J Virol; 1995 Jun; 69(6):3299-307. PubMed ID: 7745677
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction of feline leukaemia virus-neutralizing antibodies by immunization with synthetic peptides derived from the FeLV env gene.
    Weijer K; Pfauth A; van Herwijnen R; Jarrett O; Meloen RH; Tomee C; Osterhaus AD
    Vaccine; 1993; 11(9):946-56. PubMed ID: 7692683
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hypervariable epitope constructs representing variability in envelope glycoprotein of SIV induce a broad humoral immune response in rabbits and rhesus macaques.
    Meyer D; Anderson DE; Gardner MB; Torres JV
    AIDS Res Hum Retroviruses; 1998 Jun; 14(9):751-60. PubMed ID: 9643375
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mapping of B-neutralizing and T-helper cell epitopes on the bovine leukemia virus external glycoprotein gp51.
    Callebaut I; Vonèche V; Mager A; Fumière O; Krchnak V; Merza M; Zavada J; Mammerickx M; Burny A; Portetelle D
    J Virol; 1993 Sep; 67(9):5321-7. PubMed ID: 7688821
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NMR-derived solution conformations of a hybrid synthetic peptide containing multiple epitopes of envelope protein gp120 from the RF strain of human immunodeficiency virus.
    de Lorimier R; Moody MA; Haynes BF; Spicer LD
    Biochemistry; 1994 Mar; 33(8):2055-62. PubMed ID: 7509632
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Monoclonal anti-idiotypic antibody mimicking the principal neutralization site in HIV-1 GP120 induces HIV-1 neutralizing antibodies in rabbits.
    Fung MS; Sun CR; Liou RS; Gordon W; Chang NT; Chang TW; Sun NC
    J Immunol; 1990 Oct; 145(7):2199-206. PubMed ID: 2398276
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epitopes recognized by the neutralizing antibodies of an HIV-1-infected individual.
    Profy AT; Salinas PA; Eckler LI; Dunlop NM; Nara PL; Putney SD
    J Immunol; 1990 Jun; 144(12):4641-7. PubMed ID: 1693639
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas.
    Carrow EW; Vujcic LK; Glass WL; Seamon KB; Rastogi SC; Hendry RM; Boulos R; Nzila N; Quinnan GV
    AIDS Res Hum Retroviruses; 1991 Oct; 7(10):831-8. PubMed ID: 1720630
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neutralization of multiple laboratory and clinical isolates of human immunodeficiency virus type 1 (HIV-1) by antisera raised against gp120 from the MN isolate of HIV-1.
    Berman PW; Matthews TJ; Riddle L; Champe M; Hobbs MR; Nakamura GR; Mercer J; Eastman DJ; Lucas C; Langlois AJ
    J Virol; 1992 Jul; 66(7):4464-9. PubMed ID: 1602554
    [TBL] [Abstract][Full Text] [Related]  

  • 40. B cell epitope mapping of human immunodeficiency virus envelope glycoproteins with long (19- to 36-residue) synthetic peptides.
    Neurath AR; Strick N; Lee ES
    J Gen Virol; 1990 Jan; 71 ( Pt 1)():85-95. PubMed ID: 1689372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.